Seres Therapeutics Inc (NASDAQ:MCRB) has a beta value of 2.00 and has seen 6.77 million shares traded in the last trading session. The company, currently valued at $158.74M, closed the last trade at $0.89 per share which meant it gained $0.12 on the day or 15.17% during that session. The MCRB stock price is -130.34% off its 52-week high price of $2.05 and 39.33% above the 52-week low of $0.54. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.26 million shares traded. The 3-month trading volume is 3.90 million shares.

The consensus among analysts is that Seres Therapeutics Inc (MCRB) is Buy stock at the moment, with a recommendation rating of 2.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.21.

Seres Therapeutics Inc (NASDAQ:MCRB) trade information

Sporting 15.17% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MCRB stock price touched $0.89 or saw a rise of 1.11%. Year-to-date, Seres Therapeutics Inc shares have moved -36.77%, while the 5-day performance has seen it change 52.91%. Over the past 30 days, the shares of Seres Therapeutics Inc (NASDAQ:MCRB) have changed 25.58%. Short interest in the company has seen 17.85 million shares shorted with days to cover at 5.75.

Wall Street analysts have a consensus price target for the stock at $1.25, which means that the shares’ value could jump 28.8% from current levels. The projected low price target is $1.25 while the price target rests at a high of $1.25. In that case, then, we find that the current price level is -40.45% off the targeted high while a plunge would see the stock gain -40.45% from current levels.

Seres Therapeutics Inc (MCRB) estimates and forecasts

Figures show that Seres Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -4.77% over the past 6 months, with this year growth rate of 57.30%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be -100.00%.

4 have an estimated revenue figure of 12.5M for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 18.22% over the past 5 years.

MCRB Dividends

Seres Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders

Insiders own 13.19% of the company shares, while shares held by institutions stand at 37.56% with a share float percentage of 43.28%. Investors are also buoyed by the number of investors in a company, with Seres Therapeutics Inc having a total of 91.0 institutions that hold shares in the company. The top two institutional holders are FLAGSHIP PIONEERING INC. with over 23.12 million shares worth more than $16.73 million. As of 2024-06-30, FLAGSHIP PIONEERING INC. held 15.8226% of shares outstanding.

The other major institutional holder is FMR LLC, with the holding of over 22.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $16.44 million and represent 15.5489% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 4.04% shares in the company for having 6.89 shares of worth $6.1 million while later fund manager owns 3.04 shares of worth $2.69 million as of Jun 30, 2024 , which makes it owner of about 1.78% of company’s outstanding stock.